Zymeworks (ZYME)

Its best-known program is zanidatamab, a HER2-targeted bispecific antibody developed from Zymeworks’ technology and partnered for commercial development in key markets. HER2 is an established cancer target, best known for its role in breast and gastric cancers, but it is also expressed in other solid tumours. Zanidatamab is designed to attach to two distinct sites on HER2, a structure that may support stronger receptor clustering, immune engagement and anti-tumour activity. The programme is studied across multiple HER2-expressing cancers, giving Zymeworks exposure to a broad area of oncology drug development.

Beyond zanidatamab, Zymeworks maintains a pipeline of preclinical and clinical-stage candidates that apply its engineering expertise to new targets and drug formats. The company’s approach combines discovery biology, antibody design, translational research and development capabilities, with the aim of producing medicines that are differentiated by mechanism, potency, tolerability or combination potential.

As a listed biopharmaceutical stock, Zymeworks is tied to the high-risk, high-reward profile typical of oncology developers. Its value depends on clinical trial outcomes, regulatory decisions, partner execution, intellectual property protection and the commercial prospects of approved or late-stage therapies. Investors generally view the company through the strength of its technology platform, the progress of partnered HER2 programmes and the depth of its next-generation oncology pipeline.